Shanghai Junshi Bioscience Co., Ltd.
Clinical trials sponsored by Shanghai Junshi Bioscience Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for lung cancer patients when targeted drugs stop working Results expected Sep 2026 (estimated)
- New drug combo targets Hard-to-Treat cancers Results expected Dec 2026 (estimated)
- New hope for tough lymphoma: experimental drug JS203 enters human testing Results expected Dec 2026 (estimated)
- Can an immunotherapy drug keep liver cancer at bay after surgery? Results expected Dec 2026 (estimated)
- Promising immunotherapy combo takes on advanced liver cancer Results expected Dec 2026 (estimated)
-
Can two drugs together tackle tough lung cancer?
Disease control Stopped earlyThis trial is testing whether combining two drugs—glumetinib and toripalimab—can help people with advanced non-small cell lung cancer that has not responded to or is no longer controlled by standard treatments. The study is enrolling adults whose cancer has a specific marker (PD-…
Phase 1/2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can an immune booster shrink Hard-to-Treat stomach tumors?
Disease control Stopped earlyThis phase 2 trial is testing whether toripalimab, an immunotherapy drug, can shrink tumors in people with advanced stomach or gastroesophageal junction cancer that has worsened after at least two prior treatments. Participants receive toripalimab every three weeks. The main goal…
Phase 2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can an immune checkpoint blocker outperform interferon in keeping mucosal melanoma at bay?
Disease control Stopped earlyThis phase II trial tests whether toripalimab, an anti-PD-1 antibody, can prevent mucosal melanoma from returning after surgical removal better than high-dose interferon. Adults aged 18 to 75 whose melanoma was completely removed and who have not had prior adjuvant therapy are el…
Phase 2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Experimental antibody aims to quiet spinal inflammation without X-Ray damage
Disease control Stopped earlyThis phase 2 trial tests an experimental drug called JS005 in Chinese adults with active non-radiographic axial spondyloarthritis, a form of inflammatory back pain that does not yet show damage on X-rays. Participants receive either a low, medium, or high dose of JS005 or a place…
Phase 2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New combo therapy tested for advanced cancers
Disease control Stopped earlyThis early-stage study tested a new drug (JS004) combined with another immunotherapy (Toripalimab) in 31 people with advanced solid tumors like liver, esophageal, stomach, cervical, or colorectal cancer. The goal was to check safety and see if the combination could help control t…
Phase 1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC